International Journal of Colorectal Disease

, Volume 34, Issue 2, pp 347–351 | Cite as

The role of the NOD2/CARD15 gene in surgical treatment prediction in patients with Crohn’s disease

  • L. Kunovsky
  • Z. Kala
  • F. MarekEmail author
  • J. Dolina
  • K. Poredska
  • L. Kucerova
  • K. Benesova
  • L. Mitas
Short Communication



Crohn’s disease (CD) belongs to chronic disorders with unpredictable disease course. The aim of this study was to identify how genetic testing (NOD2/CARD15) can be used in patients with CD to predict the need for surgical treatment (to define an aggressive type of disease where the patient can profit from early surgery).


The patients who were tested genetically had undergone a surgery due to CD at the Department of Surgery University Hospital Brno Bohunice between 2010 and 2016. The control group consisted of patients with CD who had been diagnosed with CD at least 5 years prior to the testing and had not required any surgical intervention. The second control group was healthy subjects.


In total, there were 117 operated patients for CD, 77 patients with CD that had not undergone surgery for CD and 30 healthy subjects. For patients with at least one genetic mutation, the risk of the necessity of surgical treatment of CD is 1.96 times higher than for patients with no mutation. Patients with two or more mutations were generally operated on at a younger age, in a shorter time after being diagnosed and each patient had a partial resection of the ileum.


The group of operated patients with CD had a significantly higher distribution of at least one genetic mutation as opposed to the non-operated group. In patients with two or more mutations, the disease course was more aggressive. This group of patients might profit from the conservative top-down or early surgical therapy.


Crohn’s disease Inflammatory bowel disease Disease course Genetics NOD2/CARD15 Surgery Intestinal resection Czech cohort 


Compliance with ethical standards

Ethical standard statement

All procedures which followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. 1.
    Kunovsky L, Marek F, Kala Z, Dolina J, Moravcik P, Can V et al (2017) Possibilities of minimally invasive surgery in patients with Crohn’s disease and ulcerative colitis. Gastroenterol Hepatol 71(1):29–35CrossRefGoogle Scholar
  2. 2.
    Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, Nuñez G, Cho JH (2001) A frameshift mutation in NOD2 associated with susceptibility to Crohn’s disease. Nature 411(6837):603–606CrossRefGoogle Scholar
  3. 3.
    Niess JH, Klaus J, Stephani J, Pflüger C, Degenkolb N, Spaniol U, Mayer B, Lahr G, von Boyen GBT (2012) NOD2 polymorphism predicts response to treatment in Crohn’s disease—first steps to a personalized therapy. Dig Dis Sci 57(4):879–886CrossRefGoogle Scholar
  4. 4.
    Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO et al (2017) 3rd European evidence-based consensus on the diagnosis and Management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 11(1):3–25CrossRefGoogle Scholar
  5. 5.
    Annese V, Lombardi G, Perri F, D’Incà R, Ardizzone S, Riegler G et al (2005) Variants of CARD15 are associated with an aggressive clinical course of Crohn’s disease—an IG-IBD study. Am J Gastroenterol 100(1):84–92CrossRefGoogle Scholar
  6. 6.
    Cleynen I, González JR, Figueroa C, Franke A, McGovern D, Bortlík M, Crusius BJA, Vecchi M, Artieda M, Szczypiorska M, Bethge J, Arteta D, Ayala E, Danese S, van Hogezand RA, Panés J, Peña SA, Lukas M, Jewell DP, Schreiber S, Vermeire S, Sans M (2013) Genetic factors conferring an increased susceptibility to develop Crohn’s disease also influence disease phenotype: results from the IBDchip European Project. Gut 62(11):1556–1565CrossRefGoogle Scholar
  7. 7.
    Adler J, Rangwalla SC, Dwamena BA, Higgins PD (2011) The prognostic power of the NOD2 genotype for complicated Crohn’s disease: a meta-analysis. Am J Gastroenterol 106(4):699–712CrossRefGoogle Scholar
  8. 8.
    Seiderer J, Brand S, Herrmann KA, Schnitzler F, Hatz R, Crispin A, Pfennig S, Schoenberg SO, Göke B, Lohse P, Ochsenkühn T (2006) Predictive value of the Card15 variant 1007fs for the diagnosis of intestinal stenoses and the need for surgery in Crohn’s disease in clinical practice: results of a prospective study. Inflamm Bowel Dis 12(12):1114–1121CrossRefGoogle Scholar
  9. 9.
    Vermeire S, Van Assche G, Rutgeerts P (2010) Role of genetics in prediction of disease course and response to therapy. World J Gastroenterol 16(21):2609–2615CrossRefGoogle Scholar
  10. 10.
    Büning C, Genschel J, Bühner S, Krüger S, Kling K, Dignass A et al (2004) Mutations in the NOD2/CARD15 gene in Crohn’s disease are associated with ileocecal resection and are a risk factor for reoperation. Aliment Pharmacol Ther 19(10):1073–1078CrossRefGoogle Scholar
  11. 11.
    Jürgens M, Brand S, Laubender RP, Seiderer J, Glas J, Wetzke M, Wagner J, Pfennig S, Tillack C, Beigel F, Weidinger M, Schnitzler F, Kreis ME, Göke B, Lohse P, Herrmann K, Ochsenkühn T (2010) The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn’s disease independent of the IL23R genotype. J Gastroenterol 45(7):721–731CrossRefGoogle Scholar
  12. 12.
    Maconi G, Colombo E, Sampietro GM, Lamboglia F, D’Incà R, Daperno M et al (2009) CARD15 gene variants and risk of reoperation in Crohn’s disease patients. Am J Gastroenterol 104(10):2483–2491CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of SurgeryUniversity Hospital Brno Bohunice, Faculty of Medicine, Masaryk UniversityBrnoCzech Republic
  2. 2.Department of GastroenterologyUniversity Hospital Brno Bohunice, Faculty of Medicine, Masaryk UniversityBrnoCzech Republic
  3. 3.Institute of Biostatistics and Analyses, Faculty of MedicineMasaryk UniversityBrnoCzech Republic
  4. 4.Institute of Health Information and Statistics of the Czech RepublicPragueCzech Republic

Personalised recommendations